INDOCO.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 07:39):

Stats
Šios dienos apimtis	57 992.00
Vidutinė apimtis	100 381
Rinkos kapitalizacija	30.42B
EPS	INR0 ( 2024-01-23 )
Kita pelno data	( INR2.80 ) 2024-05-21
Last Dividend	INR2.25 ( 2023-09-18 )
Next Dividend	INR0 ( N/A )
P/E	29.97
ATR14	INR0.454 (0.14%)

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: 0.48 (neutral)

Signal:(57.733) Neutral

Indoco Remedies Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
ICICIGI.NS	0.898
RADIOCITY.NS	0.889
INSECTICID.NS	0.883
INDUSTOWER.NS	0.881
HDFCAMC.NS	0.878
SAREGAMA.NS	0.876
IDEA.NS	0.874
PUNJABCHEM.NS	0.869
SHOPERSTOP.NS	0.866
TCIFINANCE.NS	0.865

10 Labiausiai neigiamai susiję koreliacijos
SICAGEN.NS	-0.883
SMLT.NS	-0.881
OIL.NS	-0.875
STAMPEDE.NS	-0.873
STERTOOLS.NS	-0.871
NEWGEN.NS	-0.871
KEERTI.NS	-0.869
SURYAROSNI.NS	-0.863
ROTO.NS	-0.862
PDSMFL.NS	-0.856

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Indoco Remedies Limited Koreliacija - Valiuta/Žaliavos

-0.02
( neutral )

0.16
( neutral )

-0.29
( neutral )

0.35
( neutral )

0.01
( neutral )

-0.27
( neutral )

Indoco Remedies Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR16.40B
Bruto pelnas:	INR11.19B (68.21 %)
EPS:	INR15.44

FY	2022
Pajamos:	INR16.40B
Bruto pelnas:	INR11.19B (68.21 %)
EPS:	INR15.44

FY	2022
Pajamos:	INR15.04B
Bruto pelnas:	INR10.40B (69.16 %)
EPS:	INR16.80

FY	2021
Pajamos:	INR12.19B
Bruto pelnas:	INR8.59B (70.49 %)
EPS:	INR10.10

Financial Reports:

No articles found.

Indoco Remedies Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.750 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR2.25 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Indoco Remedies Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 2.93 - low (50.00%) | Divividend Growth Potential Score: 3.59 - Decrease likely (28.23%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.667	2005-09-15
Last Dividend	INR2.25	2023-09-18
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR20.23	--
Avg. Dividend % Per Year	0.26%	--
Score	1.79	--
Div. Sustainability Score	2.93
Div.Growth Potential Score	3.59
Div. Directional Score	3.26	--

Next Divdend (Est)
(2024-05-20)

INR2.51 Estimate 3.18 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.79

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.000	0.52%
2019	INR0.300	0.14%
2020	INR0.300	0.16%
2021	INR1.500	0.49%
2022	INR0.750	0.17%
2023	INR2.25	0.55%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%
ELDEHSG.NS	Dividend Junior	2023-09-15	Annually	3	0.63%
AHLADA.NS	Dividend Junior	2023-09-22	Annually	6	0.95%
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0571	1.500	8.86	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0969	1.500	-0.0350	-0.0524	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	14.32	2.00	5.23	10.00	[0 - 30]
freeCashFlowPerShareTTM	14.32	2.00	2.84	5.68	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.691	1.000	1.820	1.820	[0.2 - 0.8]
operatingProfitMarginTTM	0.104	1.000	9.92	9.92	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				2.93

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	29.81	1.000	7.09	0	[1 - 100]
returnOnEquityTTM	0.0969	2.50	-0.0225	-0.0524	[0.1 - 1.5]
freeCashFlowPerShareTTM	14.32	2.00	5.23	5.68	[0 - 30]
dividendYielPercentageTTM	0.685	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	14.32	2.00	5.23	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.449	1.500	-0.338	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0742	1.000	-0.645	0	[0.1 - 0.5]
Total Score				3.59

Indoco Remedies Limited

Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Otorex, Mofloren-D, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Cal Aid, SM Fibro, MCBM DHA, and Apispur; urology products, such as Carmicide and Cital; Cloben G and Scabex for dermatology; ATM for anti-infectives; Hemsyl for blood related; MCBM 69 and D Chiro for gynecological; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.